News | Magnetic Resonance Imaging (MRI) | May 13, 2020

First 'biomarker' for regenerative medicine may help researchers identify the people most likely to benefit from stem cell treatment

Experimental Protocol and Representative MRI of Brains at Various Key Points in That Protocol.

Experimental Protocol and Representative MRI of Brains at Various Key Points in That Protocol. (A) Experimental timeline. (B) Representative T2WI (using an 11.7T MRI) of the brain of a postnatal day (PND) 11 pup, 1 day after inducing left HII and prior to hNSC transplantation. Note the beginning of an increasingly intense “water signal” (white) on the left (“HII lesion”). (C) Representative T2WI (using an 11.7T MRI) 3 days post-HII, shortly after implantation of SPIO pre-labeled hNSCs into the contralateral cerebral ventricle (“Lateral Vent”). Note the “HII lesion” on the left becoming hyperintense (white) and the black signal void of the SPIO-labeled hNSCs in the lateral ventricle (black arrow). Red arrows denote the needle track. In contrast to what occurs in the intact brain (Figure S4), in a brain subjected to left HII, the implanted SPIO-labeled hNSCs (black signal void) (black arrow) migrate from the right (“R”) to the left (“L”) hemisphere to enter the lesion. (D and E) Shown here (using a 4.7T MRI) are SPIO-labeled hNSCs (black signal void) (black arrow) at 1 month post-implantation into the contralateral ventricle (D) and, in the same representative animal, at 3 months post-implantation (E)–stably integrated and surrounding a much-reduced residual lesion, with no interval enlargement of the graft or ventricles.


May 13, 2020 — Scientists at Sanford Burnham Prebys Medical Discovery Institute and Loma Linda University Health have demonstrated the promise of applying magnetic resonance imaging (MRI) to predict the efficacy of using human neural stem cells to treat a brain injury — a first-ever "biomarker" for regenerative medicine that could help personalize stem cell treatments for neurological disorders and improve efficacy. The researchers expect to test the findings in a clinical trial evaluating the stem cell therapy in newborns who experience a brain injury during birth called perinatal hypoxic-ischemic brain injury (HII). The study was published in Cell Reports.

"In order for stem cell therapies to benefit patients, we need to be thoughtful and scientific about who receives these treatments," said Evan Y. Snyder, M.D., Ph.D., professor and director of the Center for Stem Cells and Regenerative Medicine at Sanford Burnham Prebys, and corresponding study author. "I am hopeful that MRI, which is already used during the course of care for these newborns, will help ensure that infants who experience HII get the best, most appropriate treatment possible. In the future, MRI could help guide the use of stem cells to treat--or in some instances, not treat--additional brain disorders such as spinal cord injury and stroke."

Scientists now understand that, in many instances, human neural stem cells are therapeutic because they can protect living cells--in contrast to "re-animating" or replacing nerve cells that are already dead. As a result, understanding the health of brain tissue prior to a stem cell transplant is critical to the treatment's potential success. Tools that help predict the efficacy of neural stem cell therapy could increase the success of clinical trials, which are ongoing in people with Parkinson's disease, spinal cord injury and additional neurological conditions, while also sparing people who will not respond to treatment from an invasive procedure that offers false hope.

"We know that stem cell therapies hold extraordinary promise, but, like other medicines, they also need to be given at the right time and to the right patients," said Steve Lin, Ph.D., senior science officer at the California Institute for Regenerative Medicine, which partially funded the research. "This study suggests that a readily available technique, MRI — which is already used in many brain injuries to determine the extent of neurological damage--may be a useful tool to determine who will or will not benefit from neural stem treatment."

Protecting newborns from brain damage

Snyder, a neonatologist and pediatric neurologist, has long envisioned using human neural stem cells to protect newborns with acute perinatal HII from brain damage. He and his colleagues made the discovery that MRI could be used as an objective, quantifiable, readily available basis for inclusion and exclusion criteria for this treatment while engaged in preclinical studies required prior to starting human clinical trials for babies with HII. This birth injury affects two to four newborns out of every 1,000 babies born in the U.S. and is attributable to a number of complications, including umbilical cord compression, disrupted maternal blood pressure and maternal infection.

"My hope is that human neural stem cells can help rescue enough injured and vulnerable — though not dead — neural cells," explained Snyder. "This could help prevent the most severely affected infants from developing cerebral palsy, epilepsy, intellectual disability or other neurological disorders that often arise after HII if left untreated."

In the study, the scientists used MRI to measure two areas surrounding the regions of HII brain injury in rats: the penumbra, a region that consists of mildly injured, "stunned" neurons; and the core, an area that consists of dead neurons. They found that rats with a larger penumbra and smaller core that received human neural stem cells had better neurological outcomes — including improved memory — demonstrated by the ability to swim to a hidden platform (Morris Water Maze test), and a greater willingness to venture into a brightly lit area (open field test).

In these rats, the penumbra--to which the neural stem cells homed avidly — became normal tissue (based on MRI and histological standards), while the core remained unimproved and attracted few cells. Penumbra that did not receive cells became part of the core, populated by dead neurons--indicating the benefit of the stem cell treatment.

"This approach to brain lesion classification is a powerful patient stratification tool that allows us to identify newborns who may benefit from this stem cell therapy — and protect others from undergoing unnecessary treatment," said Snyder. "Based on our findings, only newborns with a large penumbral volume in relation to core volume should receive a transplant of human neural stem cells. Equally important, newborns so severely injured that only a core is present, or babies with such a mild case of HII that not even a penumbra is present, should not receive human neural stem cells, as the treatment is unlikely to be impactful."

For more information: www.sbpdiscovery.org

Related Content

News | Digital Pathology

October 18, 2021 — Histolix, a leading developer of direct-to-digital read pathology solutions, announced it has ...

Time October 18, 2021
arrow
News | Women's Health

October 11, 2021 — Electrical engineering professor Magda El-Shenawee’s effort to develop a more accurate and less ...

Time October 11, 2021
arrow
News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Time October 06, 2021
arrow
News | Radiology Business

September 27, 2021 — Esaote, an Italian company leader in the biomedical equipment sector – ultrasound, MRI and software ...

Time September 27, 2021
arrow
News | Prostate Cancer

September 24, 2021 — Scientists have identified two subtypes of metastatic prostate cancer that respond differently to ...

Time September 24, 2021
arrow
News | Cardiac Imaging

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by ...

Time September 23, 2021
arrow
News | Women's Health

September 22, 2021 — Radiation therapy is an effective and widely used treatment for breast cancer. While the benefits ...

Time September 22, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to ...

Time September 20, 2021
arrow
News | Contrast Media Injectors

September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthcare ...

Time September 16, 2021
arrow
Subscribe Now